Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice

• Published in: npj vaccines Vol. 8; no. 1; pp. 96 - 18
• Main Authors: Jangra, Sonia, Landers, Jeffrey J., Laghlali, Gabriel, Rathnasinghe, Raveen, Warang, Prajakta, Park, Seok-Chan, O’Konek, Jessica. J., Singh, Gagandeep, Janczak, Katarzyna W., García-Sastre, Adolfo, Arya, Nandini, Karadag, Dilara, Baker, James R., Schotsaert, Michael, Wong, Pamela T.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 29.06.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250/255/2514; 631/250/262/2106; 631/250/590/2291; Adjuvants; Biomedical and Life Sciences; Biomedicine; COVID-19; COVID-19 vaccines; Immunity (Disease); Immunization; Immunogenicity; Infectious Diseases; Medical Microbiology; Public Health; Rodents; Severe acute respiratory syndrome coronavirus 2; Vaccine; Vaccines; Virology

Multiple FDA-approved SARS-CoV-2 vaccines currently provide excellent protection against severe disease. Despite this, immunity can wane relatively fast, particularly in the elderly and novel viral variants capable of evading infection- and vaccination-induced immunity continue to emerge. Intranasal...